Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K. Ishikawa T, et al. Among authors: kawakita y. J Med Chem. 2011 Dec 8;54(23):8030-50. doi: 10.1021/jm2008634. Epub 2011 Nov 4. J Med Chem. 2011. PMID: 22003817
Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.
Kawakita Y, Banno H, Ohashi T, Tamura T, Yusa T, Nakayama A, Miki H, Iwata H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Ohta Y, Ishikawa T. Kawakita Y, et al. J Med Chem. 2012 Apr 26;55(8):3975-91. doi: 10.1021/jm300185p. Epub 2012 Apr 10. J Med Chem. 2012. PMID: 22439974
Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.
Kawakita Y, Miwa K, Seto M, Banno H, Ohta Y, Tamura T, Yusa T, Miki H, Kamiguchi H, Ikeda Y, Tanaka T, Kamiyama K, Ishikawa T. Kawakita Y, et al. Bioorg Med Chem. 2012 Oct 15;20(20):6171-80. doi: 10.1016/j.bmc.2012.08.002. Epub 2012 Aug 25. Bioorg Med Chem. 2012. PMID: 22980219
Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.
Nakayama A, Takagi S, Yusa T, Yaguchi M, Hayashi A, Tamura T, Kawakita Y, Ishikawa T, Ohta Y. Nakayama A, et al. Among authors: kawakita y. J Cancer. 2013 Aug 16;4(7):557-65. doi: 10.7150/jca.6689. eCollection 2013. J Cancer. 2013. PMID: 23983820 Free PMC article.
Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.
Imamura K, Tomita N, Kawakita Y, Ito Y, Ono K, Nii N, Miyazaki T, Yonemori K, Tawada M, Sumi H, Satoh Y, Yamamoto Y, Miyahisa I, Sasaki M, Satomi Y, Hirayama M, Nishigaki R, Maezaki H. Imamura K, et al. Among authors: kawakita y. Bioorg Med Chem. 2017 Jul 15;25(14):3768-3779. doi: 10.1016/j.bmc.2017.05.016. Epub 2017 May 11. Bioorg Med Chem. 2017. PMID: 28571972
Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.
Fushimi M, Fujimori I, Wakabayashi T, Hasui T, Kawakita Y, Imamura K, Kato T, Murakami M, Ishii T, Kikko Y, Kasahara M, Nakatani A, Hiura Y, Miyamoto M, Saikatendu K, Zou H, Lane SW, Lawson JD, Imoto H. Fushimi M, et al. Among authors: kawakita y. J Med Chem. 2019 May 23;62(10):4915-4935. doi: 10.1021/acs.jmedchem.8b01630. Epub 2019 May 3. J Med Chem. 2019. PMID: 31009559
[Drug therapy of acute schizophrenia].
Kawakita Y. Kawakita Y. Saishin Igaku. 1965 Sep;20(9):2440-8. Saishin Igaku. 1965. PMID: 5329115 Clinical Trial. Japanese. No abstract available.
166 results